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Background: In 2006, Ethicon Inc. introduced a new minimally invasive single incision sling device for the surgical
treatment of stress urinary incontinence, the Gynecare TVT Secur®. For device licensing, no new evidence of TVT
Secur efficacy and safety was needed: rather evidence was provided of the long-term follow-up of patients who
had a procedure using a predecate retropubic tension-free vaginal tape device. Before adopting TVT Secur into our
routine clinical practice, we decided to evaluate it. The objective of our Canadian multi-centre pragmatic randomized
controlled trial was to compare the effectiveness of the new single-incision device, TVT Secur, to the established TVT
device, in terms of objective cure of stress urinary incontinence (SUI) at 12 months postoperatively. Other outcomes
included: complications, symptoms, and incontinence-related quality of life.
Results: The sample size estimate for our trial was 300, but the trial stopped early because of poor recruitment. 74
women participated (40 allocated to TVT Secur, 34 to TVT). At 12 months postoperatively, 27/33(82%) of TVT Secur
group were cured, compared with 25/28(89%) of the TVT group (relative risk 0.92, 95% confidence interval 0.75 to 1.13,
p = 0.49). Most women reported little or no SUI symptoms (35/37(95%) vs 29/30(97%), >0.999). Quality of life improved
significantly from baseline for both groups (IIQ-7 mean change −25 for both groups) but did not differ between
groups (p = 0.880).
Conclusion: Our small randomized trial did not find statistically significant differences in outcomes between women
allocated to the TVT Secur device versus those allocated to the TVT device for stress urinary incontinence. Despite
the discontinuation of TVT Secur in March 2013 for commercial reasons, the importance of our study lies in making
evidence available for the many women who had a TVT Secur device implanted and their physicians who may be
considering alternative treatments. Our experience illustrates the difficulty of undertaking research on new licensed
devices in a rapidly changing surgical specialty, and further highlights the need for research before licensing if
surgeons and their patients are to be confident in the effectiveness and safety of new surgical devices.
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In 2006, Ethicon Inc. introduced a new minimally invasive
single incision sling device for the surgical treatment of
stress urinary incontinence, the Gynecare TVT Secur®
(Gynecare, Ethicon Inc., Somerville, MA, USA). For device
licensing, the new device was licensed on the basis of
evidence of efficacy and safety from a predicate device, the
tension-free vaginal tape device (TVT®, Gynecare, Ethicon
Inc., Somerville, MA, USA) rather than the new single
incision procedure, as is required by device regulations in
the USA, Europe and Canada [1]. Gynecare also provided
evidence from animal trials of pull-out strength of the
novel fixation tips that were part of the new device: these
data were not made publicly available.
Urogynecologists have for several years been concerned
about the introduction of new devices into clinical prac-
tice without new evidence of safety or effectiveness, with
the new Gynecare TVT Secur sling device being a catalyst
that prompted a number of commentaries [2,3]. At a
meeting of the Western Society for Pelvic Medicine in
2007, the surgeons decided that a trial of TVT Secur was
a research priority, given the lack of new clinical evidence
to support its adoption into practice. The objective of our
randomized trial was to compare the effectiveness of the
new TVT Secur sling device to that of the established
retropubic TVT device at 12 months postoperatively, with
the primary outcome being objective “cure” (urine leakage
less than 1 g) measured using a standardized pad test.
Despite the discontinuation of TVT Secur in March 2013
for commercial reasons, the importance of our study lies in
making evidence available for the many women who had a
TVT Secur device implanted and their physicians who may
be considering alternative treatments.
Methods
Our study was designed as a parallel group randomized trial
with follow up of participants at one year postoperatively.
Settings
The study was conducted by five participating surgeons
(three urogynecologists and two general obstetrician/
gynecologists) in four centres: two tertiary care academic
hospitals in Alberta, Canada, and one academic commu-
nity hospital and an academic regional hospital in British
Columbia, Canada. All participating surgeons had at least
8 years’ experience of incontinence surgery using TVT
slings. All undertook preceptored training with TVT Secur,
and had carried out at least five of each procedure as lead
surgeon before recruiting patients to the trial. The study was
approved by the ethics committees of each participating site.
Participants
Women electing for surgical management of stress urinary
incontinence (SUI) were eligible to participate in the trial ifthey leaked urine with increased abdominal pressure
[4,5], and were suitable for either type of surgery. Women
were excluded if they had previous incontinence surgery;
required concurrent pelvic organ prolapse surgery; had
primary complaint of overactive bladder or incontinence
caused only by bladder overflow; intended to have further
children; had Alzheimer’s or Parkinson’s disease, progres-
sive neurological disease such as multiple sclerosis, or
were immunocompromized; were are unable to understand
English or would be unavailable for follow-up. Patients agree-
ing to join the study provided written informed consent.
Baseline
Participants were asked to complete a questionnaire includ-
ing incontinence-related quality of life measures: Urogenital
Distress Inventory (UDI-6), a six item measure of uro-
genital distress, and Incontinence Impact Questionnaire
(IIQ-7), a seven-item measure of incontinence effect [6]
and a 12-item sexual function questionnaire, the Pelvic
Organ Prolapse/Urinary Incontinence Sexual Question-
naire-12, (PISQ-12) [7]. Patient characteristics including
obstetrical history and menopausal status were extracted
from patient charts.
Randomisation
Consenting patients were randomly allocated 1:1 to
receive a retropubic procedure using either a TVT Secur
sling device (“TVT Secur Group”) or the TVT tension-free
vaginal tape device (“TVT Group”). The randomisation
list was generated by the study analyst (using proc plan
procedure in SAS (SAS Institute Inc., Cary, NC, USA)
using permuted block randomisation with blocks of
varying size (2 – 6) and stratification by surgeon. Neither
the surgical team nor the patient knew the next treatment
allocation. Randomisation was carried out using an e-mail
randomisation service through the University of Calgary
Department of Obstetrics and Gynecology data manager.
Site research nurses informed the data manager when a
random allocation was needed and the patient allocation
was notified a few days before surgery to ensure that the
appropriate device was available in the operating room:
surgeons were unaware of group of allocation until day of
surgery. Neither site research nurses nor surgeons were
blinded to group of allocation for operational reasons.
Interventions
Ethicon Gynecare sling devices were used: either the
TVT Secur device (using “U” technique, akin to retropubic
placement) or the TVT device. All procedures were carried
out according to the usual practice of participating sur-
geons, consistent with the recommendations of the device
manufacturer. Preoperative urodynamic testing was used at
the clinician’s discretion [5]. Anaesthesia included general,
regional or local anaesthesia with sedation, depending on
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operative cystoscopy was carried out at the end of the
procedure for all patients. Where possible the operations
were planned as day procedures, with postoperative home
care (depending on usual hospital practice). If necessary for
clinical or logistical reasons, women were admitted to the
hospital. Surgical details including type of anaesthesia,
length of operation, length of time in hospital (hours) and
any intra- or post-operative complications (including any
difficulty experienced with the procedure) were extracted
from patient charts, verified as necessary by surgeon.
If women required re-operation for incontinence during
the 12 months following surgery, the appropriate proced-
ure was left to the surgeon’s discretion.
Outcomes
Outcomes were measured at 12 months following surgery.
All participating women were invited for outpatient
follow-up. Chart data on outcomes were collected by
study research nurses. Women who were unable to
attend clinic follow-up were asked to complete ques-
tionnaires including subjective outcome. Women were
not informed which device they had received.
Objective cure (primary outcome)
Objective evidence of SUI was obtained using a standard-
ized pad test at 12 months after surgery. Women undertak-
ing the test had retrograde bladder filling with 300 ml of
sterile water and wore pre-weighed pads while they under-
took the standardized physical activities of the 1-hour pad
test [4]. Women were considered “cured” if the pad weight
gain was less than 1 g over the test period, a definition of
cure used in other studies of surgery for SUI [8-10].
Complications and adverse events
Complications were identified from hospital and routine
6-week follow-up charts. At the 12 month follow-up, a
physician carried out an examination of operative wounds
and a digital vaginal exam to palpate for tape erosion.
Women were also asked to recall any problems they
believed they experienced as a result of surgery.
Subjective evidence of cure
Subjective cure at 12 months after surgery was defined
as either no experience of “lost or leaked urine when
you coughed, laughed, sneezed, lifted, exercised, etc.”, or
if urine loss has been “a small problem” or “no problem
at all” over the past seven days.
Incontinence-related quality of life
All women were asked at 12 months to complete UDI-6
and IIQ-7 [6]. Each measure produces a single score of 0
(no distress for UDI-6, no impact for IIQ-7) to 100 (max-
imum distress or impact). Both measures were developedfor incontinence trials, have been independently validated
[11-13], are widely used [14] and endorsed by the Inter-
national Consultation on Incontinence (ICI) [15].
Sexual function
At 12 months, women were asked if they had returned
to usual sexual activity. Sexual function was measured
using PISQ-12, which produces a single score of 0 (poor
function) to 48 (excellent function) [7] and is recom-
mended by ICI for measuring sexual function in patients
with incontinence [15].
Satisfaction with surgical outcome
Women were asked whether the outcome of surgery had
met expectations and whether they would recommend
the surgery to someone else.
Sample size
In 2007 when our study was designed, we assumed the
cure rate for the TVT Group would be 73% [9], and
wished to be able to identify a 10% difference in cure
rate for the new TVT Secur device (either worse or
improved outcome compared to TVT), a difference the
investigators believed would be required to change clinical
practice (to support or restrict its introduction). With
these assumptions, 80% power, significance level of 0.05,
and a drop-out rate of 7% (based on follow-up in our
previous randomized trial [8]), we estimated that a sample
of 150 patients per group would be required (total 300).
Recruitment was estimated to take around a year.
Unfortunately surgeon and centre recruitment was
affected by a number of issues, including uncertainty
about TVT Secur outcomes, leading to the loss of enthusi-
asm for the study by individual surgeons and centres that
had originally agreed to take part. In the end, recruitment
did not start until February 2009 and was closed in October
2010 at which time it was obvious that the trial could not
reach its target recruitment. The final recruit consented in
October 2010 and had her procedure in March 2011. The
decision to close the study early was endorsed by the trial
Data and Safety Monitoring Committee.
Analysis
Analysis was undertaken following the intention-to-treat
principle: women were analysed in the surgical group to
which they were randomized even if they received another
procedure. A single analysis was planned, when all women
had completed 12 month follow-up.
Data entry and management were carried out using
Access (Microsoft, Redmond, WA), and analyses were
carried out using SAS v9.3 (SAS Institute Inc., Cary, NC,
USA). A data entry audit was carried out on all fields of
a 10% random sample of records. Missing value, range
and logic checks identified other data discrepancies.
Ross et al. BMC Research Notes 2014, 7:941 Page 4 of 10
http://www.biomedcentral.com/1756-0500/7/941All complications were reviewed by a urogyneacologist
(MR). Descriptive statistics (means, standard deviations,
proportions) were calculated for baseline data. Primary
analysis compared the proportions of patients in the TVT
Secur Group versus the TVT Group who demonstrated
cure on the 1-hour pad test at 12 months following
surgery, using Fisher Exact Test: relative risk (RR) and
95% confidence interval (CI) were also calculated. Ana-
lyses of secondary outcomes used similar tests to compare
binomial outcomes for the two groups. Differences be-
tween groups for time, quality of life and sexual function
scores were compared using the Mann–Whitney U-test.
Changes in UDI-6, IIQ-7 and PISQ-12 scores were com-
pared between groups using t-tests. Imputation was not
used for missing data, and missing values were excluded
from all statistical tests and RRs. Results are reported
according to the CONSORT Statement for parallel group
randomized trials [16].
Approvals
Ethics approval was received from the research ethics
boards responsible for each of the participating hospitals:
University of Calgary Conjoint Health Research Ethics
Board, reference E-21528, approved 6 May 2008; UniversityFigure 1 Flow of patient recruitment and follow-up.of Alberta Health Research Ethics Board, reference 6862,
approved 25 May 2008; Interior Health Research Ethics
Board, reference 2008–032, approved 26 September 2008;
University of British Columbia, reference H08-02281,
approved 25 May 2009.
Results
Figure 1 shows a flow diagram of patient recruitment
and follow-up in the study. Four women consented to
join the study but eventually chose not to have surgery
and were not randomized. Seventy-four women were
randomized into the study: academic centres recruited
26 and 27 subjects, the academic community hospital
recruited 6 and the academic regional hospital recruited
16. Women had their surgery between February 2009
and March 2011. Forty women were randomly allocated
to the TVT Secur Group and 34 to the TVT Group. A
total of 68 (92%) were followed up at 12 months.
Baseline data are presented in Table 1. Operative
details and hospital stay are described in Table 2. All but
two women in the TVT Secur Group had the procedure
as allocated: one woman had a transobturator tape device
because the random allocation was unavailable in the OR;
another woman had the TVT Secur device replaced by a
Table 1 Patient characteristics at baseline




Mean age (years) 52.4 (SD 12.3) 47.2 (SD 10.8)
Median BMI 27.2 (IQR 7.1) 27.8 (IQR 7.8)
(1 missing)
White ethnic group 39 (98%) 32 (94%)
Current smoking 5 (13%) 6 (18%)
Nulliparous 2 (5%) 2 (6%)
No vaginal deliveries 4 (10%) 4 (12%)
Constipation 7 (18%) 11 (32%)
Postmenopausal 18 (45%) 11 (32%)
Currently on hormone
replacement treatment
11 (28%) 5 (15%)
Questionnaire findings
Median UDI-6 Score 39 (IQR 25) 39 (IQR 22)
(1 missing)
Median IIQ-7 Score 33 (IQR 29)
(2 missing)
36 (IQR 24)
Median PISQ-12 Score 36 (IQR 9)13
NA, 1 missing
37 (IQR 9)5 NA
Stress UI symptoms in past 7 days
No, or Yes but no problem
or small problem
20 (50%) 17 (50%)
Yes, a big problem 19 (48%) 17 (50%)
Yes, unknown how
much problem
1 (3%) 0 (0%)
Urge UI symptoms in past 7 days
No, or Yes but no problem
or small problem
32 (80%) 31 (91%)
Yes, a big problem 7 (18%) 3 (9%)
Unknown/Yes, unknown
how much problem
1 (3%) 0 (0%)
Night time awakening to void in past 7 days
No, or Yes but no problem
or small problem
35 (88%) 33 (97%)
Yes, a big problem 2 (5%) 1 (3%)
Unknown/Yes, unknown
how much problem
3 (8%) 0 (0%)
Notes: SD – standard deviation; BMI - Body Mass Index; IQR – inter-quartile
range; NA - not applicable.
Table 2 Operative and hospital details
TVT secur








18 (IQR 11) 21 (IQR 12) M-W p = 0.23
Type of anaesthesia FE p = 0.56
Local only 19 (48%) 16 (47%)
General only 19 (48%) 18 (53%)
Spinal with/without local 2 (5%) 0 (0%)
Complications* FE p > 0.99
Yes 3 (8%) 2 (6%)
No 36 (92%) 31 (94%)
Unknown 1 1
Hospital admission FE p = 0.66
Not admitted 38 (95%) 31 (91%)
Planned 2 (5%) 3 (9%)
Notes: IQR – inter-quartile range; M-W – Mann–Whitney U-test; FE – Fisher
Exact Test.
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intraoperative cough test found significant SUI (Figure 1).
Two subjects (one in each group) had a Novasure endo-
metrial ablation, and one TVT Group patient also had a
hysteroscopy, dilatation and curettage at the same time as
their SUI procedure. Other operative complications were as
follows: in one TVT Secur Group patient, urine continued
to leak after the device arms were tightened as much as
considered safe but no action was taken to replace the tape;
and in another TVT Secur Group patient, after a button
hole was formed in the left vagina fornix, the device wasrepositioned and the button hole repaired. One of the TVT
Group patients had a bladder perforation, and one had ≥
200 ml blood loss. Duration of operation was similar for
both groups (TVT Secur Group median 18 minutes versus
TVT Group median 21 minutes). Similar numbers of
women were admitted to hospital (two (5%) TVT Secur
Group versus three (9%) TVT Group patients) mainly for
logistic reasons (e.g. time of operation was too late to start
home care).
The primary outcome, objective cure at 12 months post-
operatively, was measured using a pad test in 33 women
in the TVT Secur Group and 28 in the TVT Group
(Table 3). Of women in the TVT Secur Group who had a
pad test, 27/33 (82%) were “cured”, compared to 25/28
(89%) in the TVT Group (relative risk 0.92, 95% CI 0.75
to 1.13). Other pelvic procedures were reported for 4
(11%) women in the TVT Secur Group, only one of
which was linked to the SUI procedure: an excision of
the vaginal mesh for an extrusion in the patient whose
button hole was repaired. No additional pelvic floor
procedures were reported for the TVT Group. At follow-
up, other complications during the 12 month postopera-
tive period were reported by three women in the TVT
Secur Group, who reported worsening of nocturia, pain in
the groin, and development of leakage following the tape
excision for an erosion (respectively): one woman in the
TVT Group reported an occasional burning sensation
under the urethra. On vaginal examination, the majority
of women had normal palpation, but the surgical tape was
palpable (non-tender) for seven (21%) women in the TVT
Secur Group and two (8%) in the TVT Group.
Questionnaires were completed by 37/40 (93%) women
in the TVT Secur Group and 31/34 (91%) in the TVT
Table 3 12 month follow-up
TVT secur n = 37 TVT n = 30 Fisher exact test results* RR (95% CI)*
PAD TEST (PRIMARY OUTCOME) p = 0.49 0.92
<1 g 27 (82%) 25 (89%) (0.75 – 1.13)
≥1 g 6 (19%) 3 (11%)
Pad test not done 4 2
Complications since hospital discharge p = 0.13 0.89(0.79 – 1.00)
Additional pelvic procedures 31 (89%) 26 (100%)
No 4 (11%) 0 (0%)
Yes 2 4
Unknown 1 (2%) 0 (0.0%)
Surgery for mesh extrusion
Vaginal examination p = 0.27 0.85
Normal palpation 26 (79%) 24 (92%) (0.69 - 1.05)
Tape palpable but non-tender 7 (21%) 2 (8%)
Unknown/not done 4 4
Bimanual examination p = 0.50 0.94
Normal 32 (94%) 25 (100%) (0.87 – 1.02)
Abnormal 2 (6%) 0 (0%)
Unknown/not done 3 5
Note: *Tests exclude women did not have test or exam, or whose status is unknown.
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between groups: subjective cure (no or little problem with
stress incontinence symptoms) was reported by women 35
(95%) in the TVT Secur Group, and 29 (97%) in the TVT
Group. Quality of life had improved for both groups as
reported using UDI-6 and IIQ-7 but did not differ between
groups: mean decrease in UDI-6 score of 28 for the TVT
Secur Group and 27 for the TVT Group; mean decrease inTable 4 12 month follow-up questionnaire results
TVT Secur group n =
Stress UI symptoms in past 7 days
No, or Yes but no problem or small problem 35 (95%)
Yes, a big problem 2 (5%)
Unknown/Yes, unknown how much problem 0
Urge UI symptoms in past 7 days
No, or Yes but no problem or small problem 36 (97%)
Yes, a big problem 1 (3%)
Night time awakening to void in past 7 days
No, or Yes but no problem or small problem 35 (95%)
Yes, a big problem 2 (5%)
Median UDI-6 score 11 (IQR 17)
Mean change from baseline −28 (SD 21)
Median IIQ-7 score 0 (IQR 14)
Mean change from baseline −25 (SD 27)
Notes: Tests exclude women did not have test or exam, or whose status is unknowIIQ-7 score of 25 for both groups. The majority of women
reported the surgery met their expectations (26 (70%) ver-
sus 28 (90%), p = 0.069), and would recommend the surgery
to someone else with similar symptoms (34 (92%) versus 30
(97%), p > 0.99). Sexual activity was reported at baseline
and 12 months by 22 women in the TVT Secur Group and
26 in the TVT Group: PISQ-12 scores improved by median
4 points in both groups (t-test p = 0.77).37 TVT group n = 31 Statistical results RR (95% CI)
FE p > 0.99 0.98
29 (97%) (0.88 – 1.08)
1 (3%)
1
FE p = 0.59 1.04
29 (94%) (0.93 – 1.16)
2 (6%)
FE p = 0.50 0.95 (0.88 – 1.02)
31 (100%)
0 (0%)
0 (IQR 11) M-W p = 0.22 n/a
−27 (SD 20) t-test p = 0.84 n/a
0 (IQR 14) M-W p = 0.71 n/a
−25 (SD 18) t-test p = 0.88 n/a
n.
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Main findings
Our trial is the first randomized trial to compare the
outcomes of TVT Secur using the U-method with out-
comes following the established TVT in women with
stress urinary incontinence without other pelvic floor
surgical procedures, and no additional unpublished trials
of this design are registered. The two tape devices are
designed to place the tape in the same position in rela-
tion to the urethra, and therefore our study provides a
direct comparison between the devices. At 12 months
postoperatively we did not find statistically significant
differences in outcome between groups for cure defined
as pad test leakage of <1 g (82% TVT Secur versus 89%
TVT), or subjective cure defined as no or small problem
caused by leakage in the past week (95% TVT Secur
versus 97% TVT). Nor did we find differences between
groups for incontinence-related quality of life or adverse
effects following surgery.
Comparison of the findings with published literature
Only one randomized trial has been published to date
directly describing the outcome of TVT Secur U technique
to that following TVT [17]. This large trial, by Barber and
colleagues, compared outcomes a year postoperatively, dif-
fering from our trial in including women with pelvic organ
prolapse or other pelvic floor problems. Among the 263
subjects randomized, 65% had concomitant surgery (hyster-
ectomy, pelvic organ prolapse surgery or colpolcleisis) [17].
Barber and colleagues’ trial did not include an objective
outcome measure, rather reporting on subjective cure (a
composite of subjective report of Incontinence Severity
Impact [18] and absence of other incontinence treatments)
at 12 months. The study found that 57% of women were
cured among the TVT Secur group, versus 61% of the
TVT group (TVT Secur was not found inferior to TVT),
but significantly more patients in the TVT Secur group
reported severe symptoms (16% versus 5%, p = 0.025). The
lower success rates in Barber’s study (compared to our cure
rates of 82% and 89%) is likely as a result of the difference
in outcome definition compared to ours, and may also have
been influenced by the concomitant surgery. In Barber’s
study, over 90% in each group would choose the same
procedure again, and women in both groups demonstrated
improvements from baseline UDI-6 and IIQ-7 scores that
were similar to the changes experienced by the women in
our study.
One other published randomized trial compared TVT
Secur (using the hammock (H) technique that places the
tape in a position replicating an obturator tape) to TVT,
recruiting 125 women, less than half of the planned 280
patients [19,20]. Recruitment was stopped early because
of a significantly lower cure rate at 2 months, and con-
cern about three severe adverse events in the TVT Securgroup (a tape erosion into the urethra, a tape placed
inside the bladder, and bleeding from the corona mortis)
[19]. Follow-up at one year after surgery found that
TVT Secur produced significantly poorer outcomes than
TVT, with fewer women having no leakage on cough
test (71% TVT Secur (H) versus 94% TVT, p = 0.01), no
pad test leakage (58% TVT Secur (H) versus 94% TVT,
p = 0.05), and subjective cure (80% TVT Secur (H) ver-
sus 98% TVT, p = 0.03) [20]. The authors suggested that
despite careful training in the TVT Secur H technique,
their adverse findings for TVT Secur might have been
the result of the TVT Secur being more clinician-
dependent and less “forgiving”, requiring extremely
careful placement of the “one chance only” device [19].
Another randomized trial compared TVT Secur out-
come to TVT and TVT-O (obturator tape), finding TVT
Secur was least effective at one year after surgery (sub-
jective cure 68% TVT Secur, 94% TVT, 92% TVT-O,
p = 0.005) [21]. Several other randomized trials reported
on outcome of TVT Secur (U or H approach) compared
to transobturator tape devices, finding lower objective
and/or subjective cure rates than transobturator tape
procedures [22-26] or that TVT Secur was not inferior
to transobturator tape procedures [27-30]. As a result of
their findings, trial authors were generally critical of
TVT Secur.
Like Barber et al’s research [17], our study found little
difference between outcomes for TVT Secur and TVT.
We have speculated about possible reasons for the posi-
tive outcomes in our study compared to other studies in
which TVT Secur produced lower effectiveness compared
to more traditional slings. One potential reason might be
that the participating surgeons opted to undertake two
TVT Secur training sessions (supported by Gynecare).
This was prompted by circulating rumours in 2008, before
published evidence was available, that TVT Secur required
a precise technique. Our second preceptor stressed the
need for “physiologic tensioning” using intraoperative
cough or Crede testing to fine tune positioning of the
mesh, and offered a technique to prevent mesh movement
as inserters were removed. These fine details were in stark
contrast to the simpler established retropubic tension-free
vaginal tape procedure. The second round of preceptored
training led to delay in the start of our trial, and may have
raised surgeons’ concerns about TVT Secur, contributing
to poor trial recruitment by collaborating surgeons.
Two rigorous systematic reviews published recently
investigated outcomes following single-incision mini-slings:
one was a systematic review with meta analysis [31]
and one a Cochrane review [32]. Both of these reviews
commented specifically on outcomes following TVT Secur
versus more traditional TVT and transobturator tapes.
Both came to similar conclusions: that TVT Secur was not
as effective as the more traditional tape devices and leads
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tions). Both of the reviews attributed the 2013 decision to
withdraw TVT Secur from the market to these findings.
The reviews found that there was too little evidence about
the outcomes of other types of single incision mini-slings
to comment confidently on the outcomes of those devices.
Adverse outcomes may yet be attributed to those other
mini-slings.
Strengths and limitations
The main strengths of our study are that it compared
outcomes for women a year following TVT Secur and
TVT, without concomitant pelvic floor surgery. We were
able to obtain outcome data for 92% of women recruited,
indicating the high level of commitment of the participating
centres. The study was carried out in a variety of hospital
settings to increase the generalizability of the findings. A
further strength was that most of the outcomes were
patient-reported by subjects who were not made aware
which device had been implanted, and whose potential
preferences or biases for one or other device would not
affect their perception of outcome. The primary outcome,
urine leakage measured during a standardized pad test was
undertaken by unblinded but independent outcome asses-
sors, research nurses who were not involved in patient care.
The principal limitation of our study was that it stopped
early because of poor recruitment, with only 74 patients
randomized, rather than the planned 300. Although recruit-
ment to surgical trials is well known to be difficult, we were
surprised that this affected our study, given the 2007 enthu-
siasm of the Western Society for Pelvic Medicine surgeons.
Two surgeons who initially expressed interest eventually
chose to carry out their own local trials, others felt their
centres had too few eligible patients or did not have
research support locally. Delays caused in seeking and
obtaining funding for our trial, and providing adequate
surgical training - at a time when other new devices be-
came available - meant that enthusiasm for TVT Secur was
insufficient to be able to recruit additional centres outside
the Western Society for Pelvic Medicine. Surgeons wishing
to undertake future studies of new devices should learn
from our experience, although identifying a device that will
prove to be the leading brand will always be a challenge.
With so few patients in our study, there is a risk that we
were unable to identify a real difference between outcomes
for the two groups: lack of statistically significant differ-
ences in outcome in our study could be as a result of type
II error. In a study of this size, only large differences in
outcome between groups would be found to be statistically
significant. None the less, the findings from our multicentre
trial add to the available evidence of effectiveness of TVT
Secur compared to TVT that will be of interest to physi-
cians who used TVT Secur and women who had one of
these devices implanted.Conclusion
The goals of introducing new minimally invasive devices
are to improve patient outcomes and ease of use for
surgeons, often by simplifying procedures while reducing
operating room time. Such goals are laudable, but must be
supported by rigorous evidence. Our small randomized
trial did not find statistically significant differences in
outcomes (cure, adverse events, or quality of life) between
women allocated to having a TVT Secur versus those
allocated to having an established TVT procedure for
stress urinary incontinence. Our trial highlights the need
for surgeons to seek adequate training and independent
evidence of effectiveness and safety before they adopt new
devices into their clinical practice. Our experience also
illustrates the difficulty of undertaking research on new
licensed devices in a rapidly changing surgical specialty,
and further highlights the need for research before licens-
ing if surgeons and their patients are to be confident in
the effectiveness and safety of new surgical devices. Our
study reiterates the wisdom of the recommendations of
the 2008 NICE guidelines for single incision sub-urethral
slings, highlighting the need to introduce these types of
device only in the context of research studies or national
registers [33].Abbreviations
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